Tufts Medical Center Parent Inc

VITAMIN D AND TYPE 2 DIABETES (D2D)

IMPROVING MEDICAL DECISION MAKING FOR OLDER PATIENTS WITH END STAGE RENAL DISEASE

TRIP-PCI: PAR1 PEPDUCIN-BASED INTERVENTIONS IN ARTERIAL THROMBOSIS

ACP EDUCATOR VIDEO PROGRAM TO PROMOTE GOAL-CONCORDANT CARE IN OLDER PATIENTS AND THOSE WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS: ADVANCING ETHICAL GOALS IN SOCIETY (AEGIS) - ABSTRACT: OVERALL EVERY DAY IN THIS COUNTRY, THOUSANDS OF OLDER AMERICANS DIE FROM SERIOUS ILLNESS, INCLUDING HUNDREDS OF PEOPLE WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (ADRD). A SIGNIFICANT GAP PERSISTS BETWEEN THE TYPE OF MEDICAL CARE PEOPLE WANT WHEN THEY HAVE AN ADVANCED, SERIOUS ILLNESS AND THE TYPE OF CARE THEY END UP RECEIVING FROM THE HEALTHCARE SYSTEM, ESPECIALLY AT THE END OF LIFE. AND FOR AFRICAN AMERICAN, HISPANIC, RURAL, AND OTHER PATIENTS, THE RATE OF NON-PATIENT-CENTERED MEDICAL CARE AT THE END OF LIFE IS DISPROPORTIONATELY EVEN HIGHER. ADVANCE CARE PLANNING (ACP) HAS BECOME INCREASINGLY IMPORTANT AS PATIENTS AND THEIR CARE PARTNERS MAKE DECISIONS OVER TIME ABOUT MEDICAL CARE, SUCH AS WHETHER TO USE A RESPIRATOR OR FOCUS ON COMFORT-ORIENTED CARE. ACP AIMS TO ENSURE PATIENTS RECEIVE CARE ALIGNED WITH THEIR VALUES. SIMPLE, EASY-TO-UNDERSTAND ACP DECISION TOOLS ARE URGENTLY NEEDED TO PROVIDE ACCURATE INFORMATION AND OVERCOME EXISTING BARRIERS. OVER THE LAST DECADE, OUR RESEARCH GROUP HAS CREATED SHORT VIDEO DECISION AIDS TO HELP PATIENTS MAKE MEDICAL DECISIONS. OUR PRIOR TRIALS HAVE SHOWN THAT AN ACP COUNSELOR VIDEO PROGRAM IN WHICH ACP COUNSELORS (I.E., NURSES OR SOCIAL WORKERS) UTILIZE VIDEO DECISION AIDS WHEN DISCUSSING ACP BETTER INFORM PATIENTS, AND LEAD TO MORE ACP DOCUMENTATION AND GOAL-CONCORDANT CARE. MAJOR LIMITATIONS OF THIS PRIOR WORK ARE: THE LIMITED NUMBERS OF RURAL PATIENTS; SMALL NUMBERS OF PATIENTS WITH ADRD; AND BRIEF INTERVENTION, TYPICALLY CONSISTING OF A SINGLE SHORT INTERACTION. TO MOVE THIS FIELD FORWARD, LONGITUDINAL TRIALS IN WHICH PATIENTS ARE FOLLOWED AND RECEIVE AN INTERVENTION OVER TIME ARE NEEDED WITH MANY PATIENTS TO PROMOTE MEDICAL DECISIONS AND THE RECEIPT OF GOALCONCORDANT CARE. THE OVERALL OBJECTIVE OF THIS U19 APPLICATION IS TO CREATE A RESEARCH PLATFORM IN WHICH THE DECISION-MAKING NEEDS OF PATIENTS AGED ≥65 WITH ADRD OR OTHER SERIOUS ILLNESS ARE ADDRESSED, WITH A FOCUS ON PATIENTS WHO HAVE BEEN OVERLOOKED IN PRIOR ACP WORK. THE GOAL WILL BE TO CONDUCT A LARGE, PRAGMATIC, RANDOMIZED, WAITLIST-CONTROLLED TRIAL. THE TRIAL WILL INCLUDE 12,174 PATIENTS AGED ≥65 WITH ADRD OR OTHER SERIOUS ILLNESS FROM THREE HEALTHCARE SYSTEMS: NORTHWELL HEALTH; THE HOSPITALS AND CLINICS AFFILIATED WITH INDIANA UNIVERSITY; AND DARTMOUTH HEALTH. WE HYPOTHESIZE THAT THE INFLUENCE OF OUR ACP COUNSELOR VIDEO PROGRAM, AS COMPARED TO USUAL CARE, WILL LEAD TO MORE ACP DOCUMENTATION AND MORE GOAL-CONCORDANT CARE. OUR SPECIFIC AIM FOR THE OVERALL SCIENCE IS: TO FULFILL THE ORGANIZATION, PROCESSES, AND INFRASTRUCTURE TO CONDUCT ALL ASPECTS OF A LARGE PRAGMATIC RANDOMIZED WAITLIST CONTROLLED TRIAL WITH AN ADMINISTRATIVE CORE, AN IMPLEMENTATION CORE, AND AN ETHICS CORE.

PRECISION MEDICINE IN THE DIAGNOSIS OF GENETIC DISORDERS IN NEONATES

THE ROLE OF VASCULAR MR-REGULATED GENES IN VASCULAR FUNCTION AND DISEASE

SMOOTH MUSCLE MINERALOCORTICOID RECEPTORS IN VASCULAR AGING AND HYPERTENSION

POLYCYSTIC KIDNEY DISEASE CLINICAL TRIALS NETWORK

REMOTE TAI CHI FOR KNEE OSTEOARTHRITIS: AN EMBEDDED PRAGMATIC TRIAL - PROJECT SUMMARY/ABSTRACT SYMPTOMATIC OSTEOARTHRITIS (OA) AFFECTS OVER 32.5 MILLION INDIVIDUALS IN THE U.S. AND IS A LEADING CAUSE OF DISABILITY AND INCREASING MEDICAL COSTS. TOXICITIES ASSOCIATED WITH DRUG THERAPIES FOR KNEE OA PAIN HAVE CAUSED THE NUMBER OF RECOMMENDED TREATMENTS TO DECREASE OVER TIME. THERE IS NOW A CRITICAL SHORTAGE OF TREATMENT OPTIONS FOR PEOPLE WITH KNEE OA, ESPECIALLY BECAUSE COMORBIDITIES THAT COMPLICATE TREATMENT SELECTION ARE HIGHLY PREVALENT IN THIS OLDER ADULT POPULATION. TAI CHI, A MULTI-DIMENSIONAL PRACTICE THAT INTEGRATES PHYSICAL, PSYCHOSOCIAL, AND BEHAVIORAL COMPONENTS, HAS EXHIBITED CLINICALLY SIGNIFICANT IMPROVEMENTS IN CHRONIC KNEE OA PAIN CONDITIONS. THE AMERICAN COLLEGE OF RHEUMATOLOGY CLINICAL PRACTICE GUIDELINES STRONGLY RECOMMEND TAI CHI AS AN INTERVENTION FOR KNEE OA. RECENT STUDIES CONDUCTED DURING THE PANDEMIC SUGGEST THAT REMOTELY DELIVERED TAI CHI IS A PROMISING AND SCALABLE STRATEGY FOR KNEE OA PAIN. HOWEVER, CRITICAL GAPS REMAIN AS TO THE REAL-WORLD EFFECTIVENESS OF REMOTE TAI CHI FOR KNEE OA AND ITS IMPLEMENTATION ACROSS MULTIPLE HEALTH CARE SYSTEMS. WE PROPOSE AN EMBEDDED, PRAGMATIC, RANDOMIZED TRIAL THAT WILL COMPARE THE EFFECTS OF A 3-MONTH TWICE WEEKLY REMOTELY DELIVERED WEB-BASED TAI CHI INTERVENTION VERSUS ROUTINE CARE ACROSS FOUR HEALTH CARE SYSTEMS (TUFTS MEDICAL CENTER, BOSTON MEDICAL CENTER, UNIVERSITY OF CALIFORNIA LOS ANGELES HEALTH, AND CLEVELAND CLINIC OHIO AND CLEVELAND CLINIC FLORIDA) IN FOUR GEOGRAPHIC REGIONS (EASTERN MASSACHUSETTS, SOUTHERN CALIFORNIA, NORTHEAST OHIO, SOUTHERN FLORIDA). WE WILL ENROLL 480 PATIENTS WITH A CLINICAL DIAGNOSIS OF KNEE OA. PARTICIPANTS WILL BE EVALUATED AT BASELINE AND 3 MONTHS, WITH ADDITIONAL FOLLOW-UP AT 6 AND 12 MONTHS. WE HYPOTHESIZE THAT IMPLEMENTATION OF REMOTELY DELIVERED TAI CHI IS FEASIBLE ACROSS FOUR HEALTH CARE SYSTEMS AND THAT TAI CHI, COMPARED TO ROUTINE CARE, WILL IMPROVE PHYSICAL HEALTH (INCLUDING KNEE-RELATED PAIN AND FUNCTION) AND MENTAL HEALTH AS WELL AS HEALTHCARE UTILIZATION. OUR INNOVATIVE STUDY IS THE FIRST RIGOROUS MULTI-SITE PRAGMATIC TRIAL OF A REMOTE TAI CHI, IN THE MULTIPLE HEALTH CARE SYSTEMS UTILIZING WEB-BASED TECHNOLOGY. IT IS DESIGNED TO IMPROVE PATIENT CENTERED OUTCOMES OF KNEE OA. THE RESULTS WILL ENABLE WIDESPREAD ADOPTION OF MIND-BODY APPROACHES FOR KNEE OA ACROSS HEALTH CARE SYSTEMS AND LAY THE GROUNDWORK FOR FUTURE TRIALS COMPARING THE EFFECTIVENESS OF DIFFERENT IMPLEMENTATION STRATEGIES.

N-GLYCOSYLATION AND OCULAR SURFACE HOMEOSTASIS

MEETING THE CHALLENGES OF COVID-19 BY EXPANDING THE REACH OF PALLIATIVE CARE: PROACTIVE ADVANCE CARE PLANNING WITH VIDEOS FOR THE ELDERLY AND ALL PATIENTS WITH DEMENTIA - THE MAJORITY OF PATIENTS AGED 65 OR OVER, AND PATIENTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (ADRD), HAVE NEVER COMMUNICATED THEIR PREFERENCES TO CLINICIANS OR COMPLETED ADVANCE CARE PLANNING (ACP) DOCUMENTS. PALLIATIVE CARE HAS THE POTENTIAL TO IMPROVE ADRD CARE, IMPROVE PATIENT-CLINICIAN COMMUNICATION AND PATIENT-CENTERED OUTCOMES, WHILE DECREASING UNWANTED BURDENSOME TREATMENTS AND IMPROVING CARE AT THE END OF LIFE. THE NOVEL CORONAVIRUS DISEASE 2019 (COVID-19) HAS ACUTELY ESCALATED THE IMPORTANCE OF INTEGRATING ACP AND PALLIATIVE CARE SERVICES INTO MEDICAL CARE. THE DEFAULT RESPONSE TO CRITICAL ILLNESS FOR PATIENTS WITH ADRD (AND ALL OTHERS) IS INTUBATION, MECHANICAL VENTILATION, AND AGGRESSIVE CARE DESPITE HAVING NO CHANGE IN MORTALITY OUTCOME. ADRD PATIENTS AND THEIR CAREGIVERS MAY PREFER TO AVOID THESE INTERVENTIONS. TO ADDRESS THESE GAPS, WE HAVE DEVELOPED A COVID-19 ACP EDUCATOR-LED, VIDEO-ASSISTED PALLIATIVE CARE INTERVENTION TO IMPROVE PATIENT-CLINICIAN COMMUNICATION, INCREASE ACP DOCUMENTATION, AND LEAD TO MORE PATIENT-CENTERED CARE AT THE END OF LIFE. WE WILL IDENTIFY ALL HOSPITALIZED PATIENTS AGED 65 AND OLDER, AND ANY PATIENT WITH ADRD, AND THEN AN ACP EDUCATOR WILL PROACTIVELY PROCEED WITH PRIMARY PALLIATIVE CARE SERVICES OF ACP, LEVERAGING CERTIFIED VIDEO DECISION AIDS THAT WE HAVE DEVELOPED. THE ACP EDUCATOR TO BE TESTED IN THIS PROPOSAL REPRESENTS A NEW ROLE AND PROACTIVE FUNCTION FOR THE PALLIATIVE CARE TEAM. THE ACP EDUCATOR, WHO WILL BE A PALLIATIVE CARE NURSE, WILL WORK WITH OLDER PATIENTS OR PATIENTS WITH ADRD AND PROXY DECISION-MAKERS TO LEARN ABOUT AND DOCUMENT PATIENTS' WISHES. THE OVERALL OBJECTIVE IS TO REDUCE THE BURDEN OF COVID-19 BY EXPANDING THE REACH OF INPATIENT PALLIATIVE CARE, ESPECIALLY FOR PATIENTS WITH ADRD. WE PROPOSE TO CONDUCT A STEPPED WEDGE CLUSTER RANDOMIZED TRIAL OF AN ACP EDUCATOR INTERVENTION AMONG HOSPITALIZED PATIENTS AGED 65 AND OVER, OR ANY PATIENT WITH ADRD AND THEIR PROXY DECISION-MAKERS IN THE WARD AND ICU SETTINGS OF TWO MAJOR HOSPITALS: BOSTON MEDICAL CENTER AND NORTH SHORE UNIVERSITY HOSPITAL. PATIENT OUTCOMES WILL BE ABSTRACTED FROM ELECTRONIC HEALTH RECORDS WITH NATURAL LANGUAGE PROCESSING. WE WILL EVALUATE INTERVENTION EFFECTIVENESS BY COMPARING THE FOLLOWING OUTCOMES AMONG 9,000 HOSPITALIZED PATIENTS: ACP DOCUMENTATION; PREFERENCES FOR RESUSCITATION; PALLIATIVE CARE CONSULTS; AND, HOSPICE USE. WE WILL CHARACTERIZE CAREGIVER-CENTERED OUTCOMES OF PATIENTS WITH ADRD, INCLUDING: (1) KNOWLEDGE, (2) CONFIDENCE IN FUTURE CARE, (3) COMMUNICATION SATISFACTION, AND (4) DECISIONAL CERTAINTY IN 600 CAREGIVERS OF PATIENTS WITH ADRD ADMITTED TO THE HOSPITAL. COVID-19 POSES A UNIQUE DILEMMA FOR OLDER AMERICANS AND PATIENTS WITH ADRD AND THEIR CAREGIVERS, WHO MUST BALANCE THEIR DESIRE TO LIVE AGAINST THE RISK OF A LONELY AND POTENTIALLY TRAUMATIC HOSPITAL DEATH. VIDEO DECISION SUPPORT IS A PRACTICAL, EVIDENCE- BASED, AND INNOVATIVE APPROACH TO ASSIST PATIENTS FACING SUCH CHOICES. IF PROVEN EFFECTIVE, THIS INNOVATIVE CARE MODEL CAN BE IMMEDIATELY DEPLOYED ACROSS THE COUNTRY TO IMPROVE THE QUALITY OF CARE FOR MILLIONS OF AMERICANS.

COMPARATIVE MODELING FOR THE PREVENTION AND CONTROL OF UTERINE CANCER - UTERINE CANCER IS THE 4TH MOST COMMON CANCER IN WOMEN AND THE 7TH MOST FREQUENT CAUSE OF CANCER-RELATED DEATH. THE DEATH RATE FROM UTERINE CANCER IS RISING FASTER THAN FOR ANY OTHER TUMOR. IMPORTANTLY, UTERINE CANCER IS ASSOCIATED WITH A PROFOUND RACIAL DISPARITY. COMPARED TO WHITE WOMEN, BLACK WOMEN ARE SIGNIFICANTLY MORE LIKELY TO DIE FROM UTERINE CANCER AND THIS DISPARITY IS INCREASING. THE OVERARCHING GOAL OF THIS PROPOSAL IS TO INFORM CANCER CONTROL AND PREVENTION STRATEGIES TO REDUCE THE INCIDENCE AND MORTALITY UTERINE CANCER BY IMPROVING THE PREVENTION, SCREENING, AND TREATMENT OF THE DISEASE. WE WILL ACCOMPLISH THIS GOAL THROUGH A COLLABORATIVE MODELING CONSORTIUM IN WHICH THREE GROUPS DEVELOP NATURAL HISTORY MODELS OF UTERINE CANCER. THESE MODELS WILL INCORPORATE KNOWN RISK FACTORS FOR UTERINE CANCER AND POPULATION LEVEL CHANGES IN THE PREVALENCE OF THESE RISK FACTORS OVER TIME. THE MODELS WILL INCLUDE PATHWAYS FOR BOTH FAVORABLE PROGNOSIS (TYPE I) UTERINE CANCER AS WELL AS MORE AGGRESSIVE (TYPE II) NEOPLASMS. ONCE DEVELOPED AND VALIDATED, WE WILL PERFORM COMPARATIVE MODELING TO EXAMINE ISSUES OF IMPORTANCE TO CLINICIANS AND POLICYMAKERS. FIRST, WE WILL EXAMINE CURRENTLY AVAILABLE AND EMERGING STRATEGIES FOR SCREENING AND PREVENTION OF UTERINE CANCER IN WOMEN. SECOND, WE WILL EXAMINE THE HARMS, BENEFITS, AND COST- EFFECTIVENESS OF TREATMENT STRATEGIES FOR UTERINE CANCER INCLUDING ADJUVANT THERAPY, TREATMENT OF METASTATIC DISEASE, AND TREATMENT OF RECURRENT DISEASE INCLUDING IMMUNOTHERAPY. THIRD, WE WILL ESTIMATE HOW CHANGING EPIDEMIOLOGIC FACTORS AND SOCIAL DETERMINANTS OF HEALTH INFLUENCE RACIAL DISPARITIES FOR UTERINE CANCER. FOURTH, WE WILL EXPLORE THE IMPACT OF THE RISING RATE OF OBESITY ON INCIDENCE AND MORTALITY OF UTERINE CANCER AND DEVELOP NOVEL, WEB-BASED TOOLS TO DETERMINE HOW STATE-LEVEL OBESITY CONTROL ACTIVITIES INFLUENCE INCIDENCE AND MORTALITY. FINALLY, WE WILL EXPLORE HOW THE DECLINING HYSTERECTOMY RATE AND CHANGING PATTERNS OF CARE FOR GYNECOLOGIC DISEASES INFLUENCE UTERINE CANCER INCIDENCE AND MORTALITY. AT THE COMPLETION OF THIS WORK, THESE DATA WILL BE WIDELY DISSEMINATED TO PATIENTS, PROVIDERS, AND POLICY MAKERS AND HAVE THE POTENTIAL TO SIGNIFICANTLY IMPACT THE CLINICAL CARE OF WOMEN WITH UTERINE CANCER AND TO GUIDE CANCER CONTROL STRATEGIES. FURTHER, THESE MODELS WILL SERVE AS AN INVALUABLE RESOURCE FOR THE UTERINE CANCER COMMUNITY AS NEW CLINICAL QUESTIONS AND CHALLENGES EMERGE.

INVESTIGATING MIXED LINEAGE KINASE 3 AS A BLOOD PRESSURE-INDEPENDENT PROTEIN KINASE G1 EFFECTOR IN HEART FAILURE - THE CGMP-DEPENDENT PROTEIN KINASE 1 ALPHA (PKG1A) OPPOSES PATHOLOGICAL LEFT VENTRICULAR (LV) HYPERTROPHY AND REMODELING VIA ROLES IN THE CARDIAC MYOCYTE (CM) AND REGULATES BLOOD PRESSURE BY PROMOTING VASCULAR SMOOTH MUSCLE CELL (VSMC) RELAXATION AND VASODILATION. DRUGS WHICH ACTIVATE PKG1, INCLUDING NITRATES, SACUBITRIL/VALSARTAN, VERICIGUAT, AND OTHERS HAVE IMPROVED MORTALITY IN HEART FAILURE WITH REDUCED LV EJECTION FRACTION (HFREF) AND THUS REPRESENT A CENTRAL ADVANCE IN HFREF TREATMENT. HOWEVER, THESE THERAPIES REMAIN LIMITED BY INCOMPLETE EFFICACY IN HFREF. FURTHERMORE, HYPOTENSION FROM PKG1-INDUCED VASODILATION HAS SEVERELY LIMITED THE PRACTICAL USE OF THESE AGENTS. THE OVERARCHING HYPOTHESIS OF THIS PROGRAM IS THAT IDENTIFYING DOWNSTREAM PKG1A ANTI-REMODELING SUBSTRATES IN THE LV CAN REVEAL NOVEL THERAPEUTIC CANDIDATES TO OVERCOME THESE CRITICAL LIMITATIONS OF CURRENT PKG1-ACTIVATING DRUGS. WE HAVE IDENTIFIED MIXED LINEAGE KINASE 3 (MLK3) AS A NOVEL PKG1A-INTERACTING PROTEIN AND ANTI-REMODELING MOLECULE. WE PROPOSE TO EXPLORE THE FOLLOWING EXCITING FINDINGS WHICH IDENTIFY MLK3 AS A TRANSLATIONALLY RELEVANT MOLECULE IN HFREF. 1) PKG1A-MLK3 INTERACTION DECLINES IN THE FAILING LV, AND MLK3 IS REQUIRED FOR PKG1A-MEDIATED THERAPEUTIC EFFECTS OF SILDENAFIL ON LV FUNCTION AFTER PRESSURE OVERLOAD, THUS IDENTIFYING DISRUPTION OF MYOCARDIAL MLK3 REGULATION BY PKG AS PROMOTING LV REMODELING AND DECREASING THE EFFICACY OF PKG1-ACTIVATING DRUGS IN HF. 2) MLK3 KINASE FUNCTION OPPOSES PATHOLOGICAL CM AND LV DYSFUNCTION AND REMODELING BUT DOES NOT AFFECT BLOOD PRESSURE IN VIVO. 3) MLK3 DELETION PROMOTES HYPERTENSION IN VIVO, BUT MLK3 REGULATION OF BLOOD PRESSURE OCCURS THROUGH MLK3 KINASE INDEPENDENT MECHANISMS AND INDEPENDENTLY OF SIGNALING BY PKG1A. WE PROPOSE TO TEST A TWO-PART NOVEL MODEL IN WHICH 1) PKG1A ACTIVATION OF MLK3 PROMOTES LV COMPENSATION TO PRESSURE OVERLOAD THROUGH MLK3 KINASE-DEPENDENT MECHANISMS IN THE CM; AND 2) MLK3 OPPOSES HYPERTENSION THROUGH KINASE-INDEPENDENT EFFECTS ON VASCULAR STIFFNESS THROUGH A ROLE IN THE VSMC. SA1 WILL USE NOVEL MLK3 CELL-SPECIFIC DELETION MODELS DEVELOPED IN OUR LAB TO DETERMINE THE CM AND SMC-SPECIFIC ROLES OF MLK3 IN BASAL REGULATION OF LV FUNCTION AND BLOOD PRESSURE AND IN THE CHRONIC LV RESPONSE TO PRESSURE OVERLOAD OR MYOCARDIAL INFARCTION. SA2 WILL DETERMINE THE KINASE DEPENDENT VERSUS KINASE INDEPENDENT EFFECTS OF MLK3 ON LV FUNCTION AND BLOOD PRESSURE. SA3 WILL DETERMINE THE TRANSLATIONAL RELEVANCE OF MLK3 TO HF TREATMENT BY TESTING THE REQUIREMENT OF MLK3 FOR LV THERAPEUTIC EFFECTS VERSUS BLOOD PRESSURE EFFECTS OF CURRENTLY AVAILABLE PKG1-ACTIVATING DRUGS. THESE STUDIES WILL DEFINE NOVEL MECHANISMS THROUGH WHICH MLK3 REGULATES BLOOD PRESSURE AND THROUGH WHICH MLK3 BLOOD PRESSURE- INDEPENDENT FUNCTIONS MEDIATE THE THERAPEUTIC EFFECT OF CURRENT PKG1-ACTIVATING DRUGS. THESE STUDIES HAVE THE POTENTIAL TO IDENTIFY MLK3 KINASE ACTIVATION AS A NOVEL THERAPEUTIC STRATEGY TO PROMOTE PKG1 THERAPEUTIC EFFECTS ON LV FUNCTION AND REMODELING BUT AVOID UNDESIRED HYPOTENSION WHICH HAS LIMITED PKG1 ACTIVATING DRUGS.

I KUA NA'U "LET ME CARRY OUT YOUR LAST WISHES" ADVANCE CARE PLANNING FOR NATIVE HAWAIIAN ELDERS

MULTILEVEL PHYSICAL ACTIVITY INTERVENTION FOR LOW INCOME PUBLIC HOUSING RESIDENTS - PROJECT SUMMARY PHYSICAL ACTIVITY HAS BEEN ASSOCIATED WITH SEVERAL CHRONIC DISEASE MARKERS FOR THE PAST 25 YEARS, AND COUNTLESS STUDIES HAVE TESTED INTERVENTIONS TO IMPROVE PHYSICAL ACTIVITY OF SEDENTARY POPULATIONS. MOST OF THESE INTERVENTION STUDIES HAVE ATTEMPTED TO IMPROVE PHYSICAL ACTIVITY BEHAVIORS BY CHANGING INDIVIDUAL LEVEL DRIVERS OF ACTIVITY, LIKE MOTIVATION, ATTITUDES, AND SELF-EFFICACY FOR BEING ACTIVE. UNFORTUNATELY, THESE EFFORTS TO CHANGE ACTIVITY LEVELS ARE OFTEN NOT SUSTAINED BEYOND THE INITIAL INTERVENTION PERIOD. ONE POSSIBLE CAUSE OF THIS LACK OF SUSTAINABILITY IS THAT INSUFFICIENT ATTENTION WAS PAID TO ENVIRONMENTAL FACTORS THAT FACILITATE PHYSICAL ACTIVITY. THUS, ATTENTION IS SHIFTING TO MORE COMPLEX ENVIRONMENTAL AND SOCIAL CONTRIBUTIONS TO PHYSICAL ACTIVITY, WITH THE AIM OF IDENTIFYING MULTI-LEVEL STRATEGIES TO BETTER TARGET INTERVENTIONS TO GROUPS THAT NEED HELP. VERY FEW TESTS OF CHANGING ENVIRONMENT LEVELS TO INCREASE PHYSICAL ACTIVITY EXIST IN THE LITERATURE. A FOCUS ON INTERVENTIONS AT ENVIRONMENTAL LEVELS, AS CALLED FOR BY RECENT REVIEWS AS WELL AS REPORTS FROM THE INSTITUTE OF MEDICINE, MIGHT PROVIDE THE LONG-TERM SUSTAINABLE CHANGE THAT IS NEEDED TO CHANGE PHYSICAL ACTIVITY IN LOW-INCOME POPULATIONS. THIS PROJECT SEEKS TO TEST A NEW MULTI-LEVEL, MULTI-COMPONENT PACKAGE TO INCREASE MODERATE INTENSITY PHYSICAL ACTIVITY LEVELS OF PEOPLE LIVING IN PUBLIC HOUSING DEVELOPMENTS. OUR AIMS ARE TO EVALUATE THE EFFECTS OF AN INTERVENTION PACKAGE FOCUSED ON THE ENVIRONMENT LEVEL TO PRODUCE CHANGES IN MODERATE PHYSICAL ACTIVITY AMONG PUBLIC HOUSING RESIDENTS. FURTHERMORE, WE WILL EVALUATE THE ADDED EFFECTS OF AN EFFICACY-TESTED INDIVIDUAL-LEVEL EHEALTH PHONE PROGRAM TO PRODUCE FURTHER CHANGES IN MODERATE INTENSITY PHYSICAL ACTIVITY. THE DESIGN OF THIS STUDY IS A PROSPECTIVE, CLUSTER RANDOMIZED CONTROLLED TRIAL, WITH HOUSING DEVELOPMENTS AS THE UNITS OF RANDOMIZATION. IN THIS FOUR GROUP, FACTORIAL, CLUSTER RANDOMIZED CONTROLLED TRIAL, WE WILL COMPARE AN ENVIRONMENTAL INTERVENTION ALONE (E ONLY), AN INDIVIDUAL INTERVENTION ALONE (I ONLY), AN ENVIRONMENTAL PLUS INDIVIDUAL INTERVENTION (E+I), ALL AGAINST A CONTROL GROUP. MEDIATION AND MODERATION OF OUR INTERVENTION WILL BE ASSESSED. LASTLY, WE WILL ASSESS FACTORS FROM THE CONSOLIDATED FRAMEWORK FOR IMPLEMENTATION RESEARCH DOMAINS TO EXAMINE FUTURE IMPLEMENTATION OF A MULTI-LEVEL PHYSICAL ACTIVITY INTERVENTION AMONG KEY INFORMANTS IN PUBLIC HOUSING DEVELOPMENTS.

MODELING MULTI-SOURCE DATA IN HODGKIN LYMPHOMA - ABSTRACT HODGKIN LYMPHOMA (HL) IS ASSOCIATED WITH EXCELLENT CURE RATES. DESPITE EARLY DISEASE CONTROL, THIS SUCCESS COMES AT CONSIDERABLE COST, WITH TREATMENT-INDUCED MORBIDITY (“LATE EFFECTS” [LE]) THAT MANIFESTS AS EARLY AS A YEAR AFTER THERAPY (E.G., 2ND CANCERS, CARDIOVASCULAR [CVD] DISEASE), COMPROMISED HEALTH-RELATED QUALITY OF LIFE (HRQL), AND EARLY MORTALITY. OVER THE PAST 20 YEARS, WHILE IMPORTANT HL CLINICAL TRIALS HAVE BEEN CONDUCTED, THERE HAS BEEN A LACK OF CONSENSUS ABOUT THE PREFERRED APPROACH TO TREATMENT, CONSIDERING BOTH SHORT- AND LONGER TERM OUTCOMES. WHILE CLINICAL TRIALS PROVIDE RICH INFORMATION ABOUT SHORT TERM DISEASE OUTCOMES, THEY DO NOT FOLLOW EFFICACY BEYOND 5 YEARS AND RARELY TRACK POST-THERAPY MORBIDITY. IN CONTRAST, HL REGISTRIES CAPTURE LONGITUDINAL OUTCOMES AND CAN BE LINKED TO OTHER SOURCES INCLUDING HEALTHCARE UTILIZATION VIA ADMINISTRATIVE CLAIMS AND CANCER REGISTRIES TO CHARACTERIZE LE AND SURVIVAL. THIS PROPOSAL REPRESENTS AN UNPRECEDENTED OPPORTUNITY TO DRAW ON THE COLLECTIVE EXPERTISE OF INTERNATIONAL CLINICAL HL ONCOLOGY EXPERTS, EPIDEMIOLOGISTS, IMAGING EXPERTS, AND METHODS & MODELING EXPERTS WITH ACCESS TO INDIVIDUAL PATIENT DATA FROM MODERN HL CLINICAL TRIALS AND REAL-WORLD REGISTRIES FROM ACROSS THE WORLD. IN PREPARATION FOR THE PROJECT, WE HARMONIZED INDIVIDUAL PATIENT DATA (IPD) FOR >12,000 HL PATIENTS FROM 12 CLINICAL TRIALS AND 4 LARGE HL REGISTRIES. BUILDING ON DATA SCIENCE PRINCIPLES, WE ESTABLISHED A COMMON DATA MODEL & UNIFYING DATA DICTIONARY, WHICH ALLOWS US TO EXPAND THE CURRENT DATABASE OVER TIME, INCORPORATING FUTURE DATA AS THEY BECOME AVAILABLE. WE WILL HARNESS THESE MULTI- SOURCE DATA TO FIRST, CREATE A MODERN PREDICTION MODEL VIA PREDICTIVE MODELING OF PRE-TREATMENT CLINICAL FACTORS; SECOND, WE WILL ESTIMATE AND VALIDATE DISEASE PROGRESSION AND EARLY EMERGENT LATE EFFECTS, ENHANCED BY THE ADDITION OF INTERIM PET IMAGING DATA AND ALTERNATIVE TREATMENT OPTIONS VIA MULTI-STATE COX PROPORTIONAL HAZARDS MODELS TO ESTIMATE TRANSITION PROBABILITIES; AND THIRD, WE WILL GENERATE A DYNAMIC DECISION MODEL TO PROJECT PRECALCULATED OUTCOMES OF INTEREST, SUCH AS SHORT TERM AND LONGER TERM OUTCOMES, INCLUDING HRQL, THE AGGREGATED, “STANDARDIZED” PRECALCULATED VISUALIZATIONS/PROJECTIONS (LIFE EXPECTANCE AND QUALITY-ADJUSTED LIFE YEARS) WILL PROVIDE A BASIS FOR COMPARING ALTERNATIVE TREATMENTS FOR A BROAD RANGE OF DISEASE SUBGROUPS AND PATIENT CHARACTERISTICS “ON THE FLY.” FURTHERMORE, BOTH THE RESULTS OF THE STATISTICAL MODELS & PARAMETER ESTIMATES FROM THE SIMULATION MODEL WILL BE VALIDATED AND RE-CALIBRATED AS NEEDED IN LARGE EXTERNAL COHORTS (I.E., GERMAN HODGKIN STUDY GROUP (GHSG) CLINICAL TRIALS DATA AND DUTCH HL REGISTRY). THE SIMULATION MODEL WILL THEN BE CONVERTED TO OPEN SOURCE, WHICH WILL ALLOW LOCAL ANALYSES THAT GO BEYOND OUR PRECALCULATED STANDARD SCENARIOS. OUR THREE-STEP APPROACH (PREDICTIVE MODELING TO MULTI-STATE MODELING TO SIMULATION/DECISION MODELING) WILL BE DESIGNED TO INCORPORATE FUTURE PROSPECTIVE DATA AS NEW/NOVEL TREATMENTS, AND KNOWLEDGE EMERGES OVER TIME. OVERALL, THIS PROJECT’S RESULTS WILL BE SIGNIFICANT AS THEY ARE EXPECTED TO DELINEATE PRECISE OUTCOMES & OPTIMAL THERAPY FOR INDIVIDUAL HL PATIENTS AND INFORM THE DEVELOPMENT OF MODELS AND PARADIGMS FOR OTHER DISEASES.

MECHANISMS OF CORNEAL NEURO-IMMUNE CROSSTALK

LIFESTYLE INTERVENTION IN PREPARATION FOR PREGNANCY (LIPP)

DIGITAL HEALTH SUPPORTED WEIGHT MANAGEMENT INTERVENTION DELIVERED BY COMMUNITY HEALTH WORKERS AMONG PUBLIC HOUSING RESIDENTS

THE SEXUALLY DIMORPHIC ROLE OF SMOOTH MUSCLE CELL ESTROGEN RECEPTOR ALPHA IN VASCULAR AGING - AGING IS ASSOCIATED WITH RISING ARTERIAL STIFFNESS (AS), AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR DISEASE (CVD) THAT LEADS TO HYPERTENSION, HEART ATTACK, STROKE, AND END ORGAN DAMAGE. THE DEVELOPMENT OF AGING-ASSOCIATED AS FOLLOWS A SEXUALLY DIMORPHIC PATTERN OF DEVELOPMENT WITH WOMEN DEVELOPING AS LATER IN LIFE AND WOMEN HAVE HIGHER RATES OF ARTERIAL STIFFNESS-ASSOCIATED CVD SUCH AS ISOLATED SYSTOLIC HYPERTENSION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION. THE MOLECULAR MECHANISMS THAT CONTRIBUTE TO SEX DIFFERENCES IN THE DEVELOPMENT OF AGING-ASSOCIATED AS ARE UNCLEAR. DETERMINATION OF THESE MECHANISMS IS AN UNMET MEDICAL NEED WITH SIGNIFICANT PUBLIC HEALTH IMPLICATIONS. WE HAVE SHOWN THAT AGING MICE FOLLOW A SIMILAR PATTERN OF DEVELOPMENT OF AS, WITH FEMALE MICE EXPERIENCING A LATE ONSET OF AS COMPARED TO MALES. ESTROGEN AND ESTROGEN RECEPTOR ALPHA (ERA) ARE PROTECTIVE IN THE PREMENOPAUSAL STATE, YET THE ROLE THAT ESTROGEN/ERA PLAYS IN VASCULAR AGING HAS NOT BEEN DEFINED. RECENT STUDIES HAVE SUGGESTED THAT UNLIGANDED ERA (ERA WITHOUT THE PRESENCE OF ESTROGEN) MAY BE DETRIMENTAL TO VASCULAR HEALTH AND DUE TO THE DECLINING LEVELS OF ESTROGEN IN FEMALES WITH AGE. FURTHER STUDIES SUPPORT THAT ERA/ESTROGEN NEGATIVELY REGULATE POLY (ADP-RIBOSE) POLYMERASE-1 (PARP1) AND THAT PARP1 TRANSCRIPTIONALLY REPRESSES THE ANGIOTENSIN II TYPE 2 RECEPTOR (AT2R), A PROTECTIVE ARM OF THE RENIN-ANGIOTENSIN- ALDOSTERONE SYSTEM. OUR PRELIMINARY DATA DEMONSTRATE THAT: 1) AGING FEMALE MICE DEVELOP INCREASED AS LATER IN LIFE THAN MALES; 2) VASCULAR ERA EXPRESSION RISES WITH AGE IN FEMALES, 3) ESTROGEN REDUCES THE BINDING OF PARP1 TO THE AT2R PROMOTER IN FEMALE SMC; 4) ELDERLY FEMALES HAVE ENHANCED INTRINSIC VASCULAR SMOOTH MUSCLE CELL STIFFNESS MEASURED BY ATOMIC FORCE MICROSCOPY COMPARED TO ELDERLY MALES; 5) IN A NOVEL MOUSE MODEL WITH ERA DELETED FROM SMOOTH MUSCLE CELL (SMC-ERA-KO), AS IS PREVENTED IN OLD FEMALES AND CIRCULATING ESTROGEN DECLINES, SUPPORTING A ROLE FOR UNLIGANDED ERA IN ARTERIAL STIFFENING AND 6) SMC-ERA-KO MICE ARE PROTECTED FROM THE AGING-ASSOCIATED INCREASE IN AORTIC PARP1 AND DECREASE IN AT2R. WE HAVE PROPOSED THREE SPECIFIC AIMS TO TEST THE NOVEL HYPOTHESIS THAT YOUNG FEMALES ARE PROTECTED FROM CVD BY ESTROGEN--MEDIATED INHIBITION OF PARP1, RESULTING IN ENHANCED AT2R ACTIVITY AND THAT WITH ADVANCING AGE, UNLIGANDED SMC-ERA CONTRIBUTES TO THE DEVELOPMENT OF ARTERIAL STIFFENING VIA THE PROMOTION OF PARP1 AND CONSEQUENTIAL INHIBITION OF AT2R EXPRESSION AND SIGNALING. SA1 WILL TEST THE HYPOTHESIS IN VITRO THAT SMC-ERA REGULATES THE PARP-1/AT2R PATHWAY IN HUMAN AORTIC SMC. SA2 WILL TEST THE IN VIVO HYPOTHESIS THAT SMC-ERA REGULATION OF PARP-1/AT2R CONTRIBUTES TO SEX DIFFERENCES IN AS IN AGING MICE BY UTILIZING OUR NOVEL SMC-ERA-KO MICE IN ADDITION TO DETERMINING THE ROLE OF SMC-PARP1 IN AGING-ASSOCIATED AS WITH OUR NOVEL SMC-PARP1-KO MICE. SA3 WILL TEST THE THERAPEUTIC POTENTIAL OF CHRONIC AT2R ACTIVATION AND PARP1 INHIBITION TO AMELIORATE AGING-ASSOCIATED AS IN MALE AND FEMALE MICE. THE LONG-TERM GOAL IS TO IDENTIFY SEX-SPECIFIC THERAPEUTIC TARGETS TO AID IN IMPROVING ARTERIAL STIFFNESS AND THE ASSOCIATED CVD OUTCOMES IN THE AGING POPULATION.

IMPROVING PRO INTERPRETATION AT THE INDIVIDUAL LEVEL FOR PATIENTS WITH CANCER USING CONVERSATIONAL AGENTS AND DATA VISUALIZATION - THERE IS INCREASING RECOGNITION OF THE IMPORTANCE OF PATIENT-REPORTED OUTCOMES (PROS) FOR ASSESSMENT OF HEALTH- RELATED QUALITY OF LIFE IN BOTH RESEARCH AND CLINICAL SETTINGS. PROS ARE ESPECIALLY IMPORTANT FOR INHERENTLY SUBJECTIVE BUT CRUCIAL CLINICAL PHENOMENA SUCH AS PAIN, MOOD, AND FATIGUE. DESPITE MUCH RESEARCH IN PROS, CONCERNS ABOUT RELIABILITY AND VALIDITY PERSIST, ESPECIALLY WHEN USED AT THE INDIVIDUAL LEVEL, PARTICULARLY AMONG PATIENTS WHO MAY STRUGGLE TO UNDERSTAND PRO QUESTIONS, SUCH AS THOSE WITH LOW HEALTH LITERACY OR UNDETECTED COGNITIVE IMPAIRMENT. OVER THE PAST DECADE, WE HAVE DEVELOPED AND TESTED A TOOL WITH THE POTENTIAL TO ENHANCE PROS AT THE INDIVIDUAL LEVEL – EMBODIED CONVERSATIONAL AGENTS (ECA), WHICH ARE COMPUTER CHARACTERS THAT SIMULATE FACE- TO-FACE CONVERSATION USING VOICE, HAND GESTURES, GAZE CUES AND OTHER NONVERBAL BEHAVIOR. WE HAVE SUCCESSFULLY USED THEM IN BEHAVIORAL INTERVENTIONS FOR POPULATIONS WITH LIMITED HEALTH LITERACY, ELDERLY PATIENTS, AND PATIENTS WITH CANCER. FACE-TO-FACE ENCOUNTERS, IN CONJUNCTION WITH WRITTEN INSTRUCTIONS SUPPORTED BY PICTURES, REMAINS ONE OF THE BEST METHODS FOR COMMUNICATING INFORMATION IN GENERAL, BUT IS PARTICULARLY EFFECTIVE FOR INDIVIDUALS WITH LIMITED HEALTH LITERACY. WE HAVE ALSO DEMONSTRATED THAT ECAS CAN BE USED AS VALID ALTERNATIVES TO STANDARD PAPER-BASED SURVEYS FOR SUBSTANCE USE SCREENING, AND THAT THE DISPLAY OF EMPATHY FOR PATIENTS AND OTHER RELATIONAL BEHAVIOR BY ECAS LEADS TO INCREASED ENGAGEMENT BY PATIENTS OVER TIME. WE WILL ADAPT OUR PRIOR WORK ON ECAS TO PRODUCE ECA-PRO, A FRAMEWORK FOR ADMINISTERING PROS OVER TIME USING AN ECA ON PATIENTS’ SMARTPHONES IN ENGLISH AND SPANISH. THE ECA-PRO SYSTEM WILL INCLUDE NOVEL USER INTERFACES TO OPTIMALLY COMMUNICATE THE RESULTS TO PATIENTS AND CLINICIANS USING CLEAR VISUALIZATIONS. TO DEMONSTRATE THE GENERALIZABILITY OF ECA-PRO, WE WILL FOCUS ON TWO CLINICAL SCENARIOS: 1) LONGITUDINAL MONITORING OF SYMPTOMS AND QUALITY OF LIFE IN PATIENTS UNDERGOING CANCER TREATMENT, AND 2) MONITORING OF MEDICATION ADHERENCE IN PATIENTS TAKING LONG-TERM ORAL ANTI-CANCER DRUGS. WE HYPOTHESIZE THAT THE ECA-PRO SYSTEM, DESIGNED FOR INDIVIDUAL-PATIENT-LEVEL INTERACTIONS AND DATA COLLECTION, WILL IMPROVE THE RELIABILITY, VALIDITY, AND OVERALL CLINICAL RELEVANCE OF PROS COLLECTED DURING CANCER TREATMENT. WE WILL DEVELOP AND EVALUATE A PRO SYSTEM THAT ENGAGES PATIENTS WITH INTERACTIVE COMMUNICATION AND EMPATHY, WHILE DELIVERING STANDARD PROS IN A WAY THAT MINIMIZES MISSING DATA AND ENABLES USER-FRIENDLY VISUAL SHARING OF RESULTS. THE ECA-PRO SYSTEM WILL CREATE A STRONG FOUNDATION FOR PRO-BASED CLINICAL DECISION-MAKING. IF SUCCESSFUL, THESE TOOLS CAN BE RAPIDLY AND BROADLY DISSEMINATED.

NEW APPROACHES TO MITIGATE LEFT VENTRICULAR INJURY WITH VA-ECMO IN ACUTE MYOCARDIAL INFARCTION - THIS NEW RO1 PROPOSAL EXPLORES NOVEL MECHANISMS OF CARDIOPROTECTION INVOLVING VENO-ARTERIAL MEMBRANE OXYGENATION (VA-ECMO) AS A PLATFORM TO REDUCE MYOCARDIAL DAMAGE AFTER ACUTE MYOCARDIAL INFARCTION (AMI). USE OF VA-ECMO HAS GROWN EXPONENTIALLY IN AMI OVER THE PAST DECADE, HOWEVER THE IMPACT OF VA-ECMO ON MYOCARDIAL INJURY HAS NOT BEEN RIGOROUSLY STUDIED. NEW MECHANISTIC INSIGHT INTO THE EFFECT OF VA-ECMO ON REPERFUSION INJURY IS NEEDED. WE RECENTLY REPORTED THE CRITICAL OBSERVATION THAT VA-ECMO INCREASES INFARCT SIZE IN SWINE MODELS OF AMI AND IN NEW DATA HAVE NOW IDENTIFIED A NOVEL PARADIGM WHEREBY VA-ECMO DEPLETES CRITICAL REGULATORS OF MITOCHONDRIAL FUNCTION AND WORSENS HEART DAMAGE IN AMI. BY EMPLOYING HIGHLY TRANSLATIONAL LARGE ANIMAL MODELS AND CLINICALLY RELEVANT INTERVENTIONAL APPROACHES, WE WILL NOW EXPLORE NEW MECHANISMS INVOLVING VA-ECMO AND MYOCARDIAL REPERFUSION INJURY, PROVIDE PENETRATING INSIGHT INTO CARDIOPROTECTION, AND GENERATE PROOF OF CONCEPT DATA FOR THE DEVELOPMENT OF NEW THERAPEUTIC APPROACHES TO LIMIT LEFT VENTRICULAR (LV) INJURY IN AMI. THE PI IS AN INTERVENTIONAL CARDIOLOGIST AND ADVANCED HEART FAILURE SPECIALIST WHO STUDIES MOLECULAR MECHANISMS OF CARDIAC REMODELING, REPERFUSION INJURY, AND THE HEMODYNAMIC EFFECTS OF CIRCULATORY SUPPORT PUMPS. THE CURRENT PROPOSAL INTEGRATES EXPERTISE IN CORONARY AND VENTRICULAR PHYSIOLOGY, MECHANICAL CIRCULATORY SUPPORT, MOLECULAR BIOLOGY, AND INTERVENTIONAL CARDIOLOGY TO THE FIELD OF MYOCARDIAL REPERFUSION INJURY, FOR WHICH NO SPECIFIC THERAPY CURRENTLY EXISTS. WE WILL TEST THE NOVEL HYPOTHESIS THAT VA-ECMO PROMOTES MYOCARDIAL DAMAGE BY WORSENING MYOCARDIAL OXYGEN SUPPLY-DEMAND MISMATCH THROUGH INCREASED LV WALL STRESS AND HYPEROXEMIA-MEDIATED INJURY RESULTING IN LOSS OF MITOCHONDRIAL INTEGRITY AND FURTHER THAT TARGETING THESE MECHANISMS WILL REDUCE INFARCT SIZE IN AMI. EXCITING NEW PRELIMINARY DATA SHOW THAT LV DECOMPRESSION OR TARGETING NORMAL ARTERIAL OXYGEN TENSION DURING VA-ECMO SUPPORT CAN MITIGATE LV INJURY BY REDUCING MYOCARDIAL OXYGEN DEMAND AND INCREASING CORONARY BLOOD FLOW. WE OBSERVED FOR THE FIRST TIME THAT VA-ECMO DECREASES LEVELS OF TAFAZZIN, A KEY ENZYME CONTROLLING MATURATION OF CARDIOLIPIN (CL), A MASTER REGULATOR OF MITOCHONDRIAL INTEGRITY. IN EXCITING NEW FINDINGS, TREATMENT WITH ELAMIPRETIDE, A CL-STABILIZING COMPOUND, BEFORE INITIATION OF VA- ECMO SIGNIFICANTLY REDUCED INFARCT SIZE COMPARED TO REPERFUSION ALONE. THESE PIONEERING APPROACHES ADDRESS MAJOR KNOWLEDGE GAPS BY STUDYING THE EFFECT OF VA-ECMO ON VENTRICULAR LOAD, CORONARY BLOOD FLOW AND OVERCOME CRITICAL BARRIERS ASSOCIATED WITH CARDIOPROTECTION IN AMI. TO TEST OUR HYPOTHESIS WE WILL EMPLOY TRANSLATIONAL STUDIES IN SWINE MODELS TO DETERMINE THE IMPACT OF VA-ECMO ON MYOCARDIAL BLOOD FLOW (SA1), MITOCHONDRIAL INTEGRITY (SA2), AND TO TEST THE THERAPEUTIC UTILITY OF A COMBINED DRUG-DEVICE APPROACH (SA3) TO LIMIT ADVERSE CARDIAC REMODELING AFTER AMI. THIS PROPOSAL HAS TREMENDOUS POTENTIAL TO IMPACT OUR UNDERSTANDING OF CORONARY AND VENTRICULAR PHYSIOLOGY, CIRCULATORY SUPPORT, AND CARDIOPROTECTION WITH IMPORTANT IMPLICATIONS FOR AMI PATIENTS AND FOR ECMO USE IN CARDIAC OR RESPIRATORY FAILURE.

ENABLING COMPARATIVE EFFECTIVENESS RESEARCH IN SILENT BRAIN INFARCTION THROUGH NATURAL LANGUAGE PROCESSING AND BIG DATA

VITAMIN D AND CALCIUM HOMEOSTASIS IN RELATION TO TYPE 2 DIABETES

EFFECT OF INTRA-ARTICULAR STEROIDS ON STRUCTURAL PROGRESSION OF KNEE OA: AN RCT

UNDERSTANDING AND ELIMINATING ONCOGENIC EGFR SIGNALING IN MALIGNANT GLIOMA

CONVERSATIONAL AGENT TO IMPROVE GUIDELINE CONCORDANT CARE FOR PEOPLE WITH CERVICAL CANCER SCREENING ABNORMALITIES - PROJECT SUMMARY / ABSTRACT CERVICAL CANCER IS ALMOST ENTIRELY PREVENTABLE WITH APPROPRIATE SCREENING AND MANAGEMENT OF ABNORMAL RESULTS, YET IN THE US, OVER 14,000 INDIVIDUALS WERE DIAGNOSED WITH CERVICAL CANCER IN 2023, AND OVER 4,000 DIED. BLACK, HISPANIC, AND LOW-INCOME INDIVIDUALS HAVE HIGHER CERVICAL CANCER INCIDENCE AND MORTALITY. OVER 20% OF THOSE DIAGNOSED WITH CERVICAL CANCER DID NOT RECEIVE APPROPRIATE DIAGNOSIS AND TREATMENT AFTER AN ABNORMAL RESULT. THE FDA APPROVED HPV SELF-COLLECTION, A NEW FORM OF SCREENING, IN MAY 2024. SELF-COLLECTION WILL EXPAND ACCESS TO SCREENING, BUT INCREASES BY NEARLY TWOFOLD THE NUMBER OF PATIENTS REQUIRING IMMEDIATE FOLLOW-UP AFTER AN ABNORMAL RESULT. FEAR OF CANCER, POOR COMMUNICATION, AND DIFFICULTY SCHEDULING FOLLOW-UP APPOINTMENTS WERE KEY BARRIERS. EMBODIED CONVERSATIONAL AGENTS (ECAS) ARE ANIMATED COMPUTER CHARACTERS THAT SIMULATE FACE-TO-FACE CONVERSATION BETWEEN A PATIENT AND A CAREGIVER, USING BOTH VERBAL AND NONVERBAL CONVERSATIONAL BEHAVIOR, TO PROVIDE A NATURAL AND INTUITIVE COMPUTER INTERFACE THAT IS ACCESSIBLE TO PATIENTS OF ALL LEVELS OF HEALTH AND COMPUTER LITERACY. WE HAVE SUCCESSFULLY DEVELOPED AND EVALUATED THIS INTERFACE IN SEVERAL CLINICAL TRIALS TO MOTIVATE HEALTH BEHAVIOR CHANGE FOR A WIDE RANGE OF POPULATIONS, INCLUDING A PILOT EVALUATION OF AN ECA THAT PROMOTES HPV VACCINATION FOR THE FAMILIES OF PATIENTS WITH CERVICAL PRE-CANCER AND CANCER. IN THIS PROJECT WE WILL ADAPT THIS TECHNOLOGY TO PRODUCE ENGLISH AND SPANISH SMARTPHONE ECAS FOR FOLLOW-UP OF ABNORMAL CERVICAL CANCER SCREENING RESULTS (ECA-CCSA). THE ECA WILL PROVIDE FOLLOW-UP RECOMMENDATIONS AND MOTIVATIONAL INTERVIEWING TO PATIENTS WITH ABNORMAL SCREENING TEST RESULTS AND WILL FACILITATE COMMUNICATION WITH CLINIC STAFF. FOLLOW-UP PROMOTION OVER TIME CAN LEAD TO COMPLETION OF NEEDED TESTING AMONG THOSE WITH BARRIERS, AND THE ECA CAN CONDUCT REPEATED CONVERSATIONS WITH PATIENTS BOTH PRIOR TO AND FOLLOWING CLINIC VISITS. WE WILL EVALUATE ECA-CCSA IN A RANDOMIZED CONTROLLED TRIAL FOR PATIENTS AGED 21 AND OLDER WITH ABNORMAL SCREENING TEST RESULTS TO EVALUATE ECA-CCSA, COMPARING USUAL CARE (UC) VERSUS USUAL CARE PLUS THE ECA (UC + ECA-CCSA). THE RESEARCH TEAM IS NATIONALLY RECOGNIZED AS LEADERS IN CERVICAL CANCER PREVENTION, HEALTH LITERACY, AND INNOVATIVE TECHNOLOGIES TO IMPROVE HEALTH. THIS STUDY WILL ADVANCE OUR RESEARCH ON THE DEVELOPMENT OF EASY-TO-USE TECHNOLOGIES TO EMPOWER PATIENTS. THIS SCALABLE APPROACH HAS SIGNIFICANT POTENTIAL TO INCREASE FOLLOW-UP AFTER AN ABNORMAL SCREENING TEST RESULT, WHICH IS TIMELY AS CLINICAL SETTINGS ARE CURRENTLY ADOPTING HPV SELF-COLLECTION TECHNOLOGIES. IF SUCCESSFUL, OUR TEAM WILL PROMOTE THE ECA-CCSA THROUGH NATIONAL NETWORKS FOR BROAD IMPLEMENTATION AND WORK TO ADAPT ECA-CCSA TO OTHER LANGUAGES AND SETTINGS.

USE OF DROPLETTE MICROMIST TECHNOLOGY DEVICE (DMTD) FOR DEEP TISSUE TREATMENT OF PRESSURE ULCERS

COMPARATIVE EFFECTIVENESS OF DEVELOPMENTAL-BEHAVIORAL SCREENING INSTRUMENTS

CREDENTIALING A CROSS-SPECIES PLATFORM TO INVESTIGATE CANCER THERAPY-ASSOCIATED CARDIOVASCULAR TOXICITY

IMMUNE RESPONSE TO CRYPTOSPORIDIOSIS IN A BIRTH COHOROT OF CHILDREN OF SOUTH INDI

COVERT CEREBROVASCULAR DISEASE DETECTED BY ARTIFICIAL INTELLIGENCE (C2D2AI): A PLATFORM FOR PRAGMATIC EVIDENCE GENERATION FOR STROKE AND DEMENTIA PREVENTION - PROJECT SUMMARY IT IS A COMMON CLINICAL OCCURRENCE THAT NEUROIMAGING SCANS OBTAINED IN THE COURSE OF ROUTINE CLINICAL CARE DISCOVER COVERT CEREBROVASCULAR DISEASE (CCD), COMPRISING COVERT BRAIN INFARCTION (CBI) AND WHITE MATTER DISEASE (WMD), IN PATIENTS WITH NO HISTORY OF STROKE OR TRANSIENT ISCHEMIC ATTACK. INDEED, EPIDEMIOLOGIC STUDIES INDICATE THAT COVERT CBI ARE FAR MORE COMMON THAN CLINICALLY-EVIDENT STROKES AND THESE IMAGING FINDINGS ARE STRONG, INDEPENDENT RISK FACTORS FOR FUTURE STROKE AND DEMENTIA. HOWEVER, THERE ARE NO PROVEN PREVENTIVE TREATMENTS OR GUIDELINES FOR INITIATING RISK FACTOR-MODIFYING THERAPY. WHILE THERE IS STRONG EVIDENCE THAT ANTIPLATELET THERAPY AND STATIN THERAPY ARE EFFECTIVE IN PREVENTING RECURRENT STROKE IN PATIENTS WITH PRIOR STROKE, IT IS UNCLEAR THE DEGREE TO WHICH THESE RESULTS APPLY TO PATIENTS WITH CCD. ADDITIONALLY, PATIENTS AND PROVIDERS ARE RARELY AWARE OF THESE FINDINGS, EVEN WHEN THEY ARE DETECTED. AS PART OF OUR PREVIOUS GRANT (R01-NS102233), WE DEVELOPED A NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM TO IDENTIFY INCIDENTALLY DISCOVERED (ID-) CCD FROM NEUROIMAGING REPORTS, WHICH WE PORTED INTO A LARGE INTEGRATED HEALTHCARE SYSTEM. WE IDENTIFIED A COHORT OF ALMOST A QUARTER MILLION PATIENTS OVER AGE 50 WHO RECEIVED EITHER A HEAD CT OR MRI AND WERE STROKE- AND DEMENTIA- FREE AT THE TIME OF THE INDEX SCAN. KEY FINDINGS OF OUR ANALYSES INCLUDE: NLP CAN IDENTIFY ID-CBI AND ID-WBD FROM NEUROIMAGE REPORTS AS WELL AS HUMAN READERS; THAT ID-CCD IS PRESENT IN ABOUT ONE-THIRD OF THESE SCANS IN AN AGE- AND VASCULAR RISK FACTOR DEPENDENT MANNER; THAT ID-CCD INCREASES THE RISK OF FUTURE STROKE AND FUTURE DEMENTIA BY APPROXIMATELY 2- TO 3-FOLD; THAT NLP IS ABLE TO EXTRACT ADDITIONAL IMPORTANT PROGNOSTIC INFORMATION ON WMD SEVERITY FROM ROUTINELY OBTAINED IMAGING REPORTS; AND FINALLY, THESE PATIENTS ARE GENERALLY NOT GIVEN RISK FACTOR MODIFYING TREATMENT FOLLOWING THE DISCOVERY OF ID-CCD. GIVEN THE DIFFICULTY OF RECRUITING THIS AT RISK POPULATION, WE NOW PROPOSE TO LEVERAGE THIS NLP SYSTEM AS A PLATFORM TO PLAN AND CONDUCT PROSPECTIVE RANDOMIZED COMPARATIVE EFFECTIVENESS STUDIES TO IDENTIFY OPTIMAL TREATMENT STRATEGIES FOR ID-CCD. THUS, OUR AIMS ARE: AIM 1: TO INFORM THE ENROLLMENT CRITERIA OF PREVENTION CLINICAL TRIALS AND ENSURE CONSISTENCY OF FINDINGS, WE WILL EXPAND THE COHORT TO KAISER PERMANENTE NORTHERN CALIFORNIA AND FURTHER CHARACTERIZE PATIENTS WITH ID-CCD REGARDING THEIR FUTURE STROKE AND DEMENTIA RISK. AIM 2: TO DETERMINE OPTIMAL TREATMENT ALGORITHMS, WE WILL LEVERAGE ESTABLISHED SIMULATION MODELS TO ESTIMATE THE TREATMENT EFFECTS OF DIFFERENT RISK FACTOR MODIFICATION ALGORITHMS IN PATIENTS WITH ID-CCD ON FUTURE STROKE AND DEMENTIA. AIM 3: TO DETERMINE OPTIMAL RECRUITMENT STRATEGIES IN DEMOGRAPHICALLY DIVERSE POPULATIONS, WE WILL EXAMINE THE FEASIBILITY OF RECRUITING THIS NOVEL POPULATION BASED ON NLP-IDENTIFIED FINDINGS BOTH PROSPECTIVELY (I.E. CONCURRENT WITH CLINICAL IDENTIFICATION) AND RETROSPECTIVELY (AS IDENTIFIED FROM PRE-EXISTING SCANS). AIM 4: BASED ON THE ABOVE FINDINGS WE WILL PLAN A MULTICENTER CLINICAL TRIAL FOR THE PREVENTION OF STROKE AND DEMENTIA IN THIS POPULATION WITH CCD.

MIR-409-3P REGULATES ANGIOGENESIS, BROWN FAT ADIPOSITY, AND INSULIN RESISTANCE

MECHANICAL UNLOADING AND DELAYED REPERFUSION PROMOTES MYOCARDIAL RECOVERY AFTER ACUTE MYOCARDIAL INFARCTION

IMPROVING KIDNEY FUNCTION ASSESSMENT IN HEALTH AND DISEASE - ACCURATE ASSESSMENT OF KIDNEY FUNCTION IS FUNDAMENTAL TO THE CARE OF ALL PATIENTS, BUT CURRENT METHODS TO ESTIMATE GFR HAVE ERROR RATES OF 35-60% IN IMPORTANT POPULATIONS AS WELL AS VARIABLE ACCURACY ACROSS RACE, ETHNICITY AND GEOGRAPHY, LEADING TO ERRORS IN CRITICAL DECISIONS, DRUG DOSING, AND DETERMINATION OF PROGNOSIS. CURRENT GFR ESTIMATES INCLUDE A COEFFICIENT FOR BLACK VS NON-BLACK WHICH MAY RESTRICT ACCESS TO CARE. AS A RESULT, THERE ARE CRITICAL KNOWLEDGE GAPS IN EVALUATION AND MANAGEMENT OF GFR IN HEALTH AND DISEASE. OUR GOAL IS TO DEVELOP A VALID AND ROBUST GFR ESTIMATE OPTIMIZED FOR AN INDIVIDUAL PERSON THAT MEETS THE CRITICAL UNMET NEED FOR A CONFIRMATORY TEST. THE CONFIRMATORY TEST WILL USE A PANEL OF ENDOGENOUS FILTRATION MARKERS TO ESTIMATE GFR (PEGFR) FROM A SINGLE BLOOD SAMPLE USING AN EQUATION THAT DOES NOT REQUIRE SERUM CREATININE OR DEMOGRAPHIC CHARACTERISTICS. OUR RESEARCH TEAM HAS EXTENSIVE EXPERIENCE IN BIOMARKER EVALUATION, GFR ESTIMATION, EPIDEMIOLOGY, LABORATORY SCIENCE AND METABOLOMICS. OUR PRELIMINARY DATA PROVIDE PROOF OF CONCEPT THAT A PANEL OF NOVEL METABOLITES THAT DOES NOT INCLUDE SERUM CREATININE OR DEMOGRAPHICS CAN ELIMINATE BIAS AND GREATLY IMPROVE PRECISION OF GFR ESTIMATES IN PATIENTS WITH HEART FAILURE AND REDUCED MUSCLE MASS; AND THAT NOVEL TECHNIQUES CAN BE USED TO PRODUCE A HIGH-ACCURACY AND PARSIMONIOUS PREDICTION MODEL. AIM 1 USING GLOBAL METABOLOMIC DISCOVERY (~1000+ METABOLITES) ON FIVE COHORTS (N=2583), WE WILL SELECT CANDIDATE METABOLITES BASED ON MAXIMAL JOINT ASSOCIATION WITH MGFR AS WELL AS BIOLOGICAL AND PHYSIOLOGICAL ASSESSMENT OF THEIR PROPERTIES AS FILTRATION MARKERS. MARKERS THAT SHOW ACCEPTABLE ANALYTICAL PROPERTIES IN INITIAL TESTING WILL BE INCORPORATED INTO A LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETER (LC-MS/MS) MULTIPLEX ASSAY. AIM 2: WE PROPOSE TO USE A SPECTRUM OF NOVEL APPROACHES, SUCH AS MARGINALIZING PREDICTIONS TO DOWN- WEIGHT OUTLIER METABOLITES AND KERNEL NEAREST NEIGHBOR WEIGHTED AVERAGE PREDICTIONS, TO MAXIMIZE PRECISION AS WELL AS ROBUSTNESS ACROSS MULTIPLE DIVERSE POPULATIONS AND TO COMPARE THESE APPROACHES TO A BENCHMARK MODEL DEVELOPED USING SUPERLEARNER ENSEMBLE MODELING TECHNIQUES. DEVELOPMENT AND EXTERNAL VALIDATION IN ~3036 AND ~3465 PARTICIPANTS ACROSS 8 AND 12 STUDIES, RESPECTIVELY. AIM 3: WE PROPOSE TO EVALUATE THE IMPACT OF PANEL EGFR IN PATIENTS WITH HEART AND LIVER FAILURE (N=1796) ON CLINICAL DECISIONS AND OUTCOMES. THE EXPECTED OUTCOME IS DEVELOPMENT OF PANEL EGFR THAT CAN BE USED AS A CONFIRMATORY TEST AND ULTIMATELY INCORPORATED INTO CLINICAL PRACTICE GUIDELINES. THE PROPOSAL IS HIGHLY INNOVATIVE AS IT IS COMPREHENSIVE SPANNING DISCOVERY, VALIDATION, ASSESSMENT OF CLINICAL UTILITY IN POPULATIONS NOT PREVIOUSLY BEEN STUDIED AND USE OF NOVEL STATISTICAL METHODS TO COMPUTE INDIVIDUALIZED GFR ESTIMATES. THE PROPOSAL IS SIGNIFICANT BECAUSE IT WILL ENABLE GENERALIZABLE AND ACCURATE INDIVIDUALIZED GFR ESTIMATES IN HEALTH AND DISEASE, PARTICULARLY DISEASES WITH UNACCEPTABLY GFR ESTIMATION HIGH ERROR RATES AND DIVERSE RACIAL, ETHNIC AND GEOGRAPHIC GROUPS.

TAI CHI AND FIBROMYALGIA

CLUSTERIN AT THE OCULAR SURFACE

TRAINING PROGRAM IN CARDIOVASCULAR RESEARCH

MATRIX METALLOPROTEASE-PAR1 REGULATION OF ATHEROSCLEROSIS

PROTEIN SIGNATURES OF APOE2 AND COGNITIVE AGING

IMPROVING OUTCOME IN NEONATAL ABSTINENCE SYNDROME

DIMENSIONS OF KIDNEY TUBULE HEALTH AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND HEART FAILURE IN MIDDLE-AGED AND OLDER ADULTS - ABSTRACT TWO CLINICAL MEASURES ARE CURRENTLY USED TO STAGE CHRONIC KIDNEY DISEASE (CKD), THE ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) AND URINE ALBUMIN-TO-CREATININE RATIO (ACR). THE ELEVATED MORBIDITY AND MORTALITY RISK THAT IS EXPERIENCED BY PERSONS WITH CKD IS OVERWHELMINGLY A RESULT OF PROGRESSIVE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) AND HEART FAILURE (HF) RATHER THAN KIDNEY FAILURE. UNFORTUNATELY, EGFR AND ACR INADEQUATELY DEPICT THE KIDNEY’S COMPLEXITY BECAUSE THEY REPRESENT GLOMERULAR FUNCTION AND INJURY RESPECTIVELY; YET THE KIDNEY IS PREDOMINANTLY COMPRISED OF TUBULES, AND THE KIDNEY TUBULES ARE RESPONSIBLE FOR MYRIAD HOMEOSTATIC FUNCTIONS THAT LIKELY HAVE MORE DIRECT INFLUENCE ON THE CARDIOVASCULAR SYSTEM THAN DOES DAMAGE TO THE GLOMERULUS. MOREOVER, PATHOLOGY STUDIES HAVE CONVINCINGLY DEMONSTRATED THAT TUBULE DAMAGE IS MORE PROGNOSTIC FOR LOSS OF KIDNEY FUNCTION THAN GLOMERULAR SCARRING. NOVEL URINE MEASURES THAT QUANTIFY THE HEALTH OF THE KIDNEY TUBULES HAVE RECENTLY ALLOWED US TO DEFINE FOUR ADDITIONAL DIMENSIONS OF KIDNEY HEALTH THAT INDEPENDENTLY INFLUENCE RISK FOR PROGRESSIVE CKD: PROXIMAL TUBULE INJURY, PROXIMAL TUBULE FUNCTION, TUBULE FIBROSIS AND REPAIR, AND TUBULE SYNTHETIC FUNCTION. OUR TEAM HAS SELECTED EIGHT DISTINCT URINE MEASURES THAT CAPTURE EACH OF THESE FOUR DIMENSIONS AND COMPRISE THE KIDNEY TUBULE HEALTH PANEL (KTHP). IN SPECIFIC, HIGH-RISK POPULATIONS, THE KTHP DIMENSIONS ARE STRONGLY ASSOCIATED WITH RISK FOR ASCVD, HF AND MORTALITY; BUT NO STUDIES HAVE EVALUATED THE CONTRIBUTIONS OF KIDNEY TUBULE HEALTH TO THE DEVELOPMENT OF ASCVD AND HF IN THE GENERAL POPULATION. OUR GLOBAL HYPOTHESIS IS THAT KIDNEY TUBULE DAMAGE AND DYSFUNCTION ARE RELATED TO THE ONSET AND PROGRESSION OF ASCVD AND HF. WITHIN TWO WELL-ESTABLISHED, GENERAL POPULATION COHORTS, CARDIA AND MESA, THIS PROPOSAL WILL ADDRESS THE FOLLOWING RESEARCH QUESTIONS THAT ARE CRITICAL TO UNDERSTANDING THE DEVELOPMENT OF EACH DIMENSION OF KIDNEY TUBULE DISEASE AND THEIR ROLE IN PROMOTING ASCVD AND HF: 1) DOES KIDNEY TUBULE DISEASE DEVELOP EARLIER AND PROGRESS FASTER WITH ADVANCING AGE THAN ACR AND EGFR? 2) IS KIDNEY TUBULE DISEASE MORE SEVERE IN BLACK AND HISPANIC PERSONS COMPARED WITH WHITE PERSONS? 3) WHICH ATHEROSCLEROTIC RISK FACTORS HAVE THE STRONGEST ASSOCIATIONS WITH EACH DIMENSION OF KIDNEY TUBULE DISEASE? 4) HOW STRONGLY ASSOCIATED IS KIDNEY TUBULE DISEASE WITH SEVERAL SUBCLINICAL CVD MEASURES? 5) HOW STRONGLY ASSOCIATED ARE KIDNEY TUBULE DISEASE MARKERS WITH ASCVD AND HF, AND DO THEY IMPROVE PREDICTION OF THESE ENDPOINTS? IF THESE AIMS ARE SUCCESSFUL, THESE EASILY MEASURED, NON-INVASIVE INDICES OF KIDNEY TUBULE HEALTH MAY HAVE VALUE FOR POPULATION SCREENING, TO PROVIDE INSIGHTS INTO RACE/ETHNIC DIFFERENCES IN KIDNEY AND CARDIOVASCULAR DISEASE, AND TO IDENTIFYING PATHWAYS FOR NOVEL THERAPEUTICS THAT TARGET KIDNEY TUBULES, SUCH AS THE SGLT2 INHIBITORS AND THE NON-STEROIDAL ALDOSTERONE ANTAGONISTS, THAT REDUCE RISK FOR BOTH KIDNEY AND CARDIOVASCULAR ADVERSE OUTCOMES.

A ROLE OF PKG1A AND INHIBITORS OF CGMP PHOSPHODIESTERASE IN POST MI VT IN MOUSE MODELS FOR TYPE II DIABETES AND METABOLIC SYNDROME

NOVEL STRATEGIES TO UNDERSTAND, PREDICT, AND PREVENT VASCULAR TOXICITY OF TARGETED CML THERAPIES - MOLECULARLY TARGETED CANCER THERAPIES, SUCH AS ABL-TARGETED TYROSINE KINASE INHIBITORS (TKIS), HAVE CONVERTING MANY TERMINAL CANCERS, INCLUDING CHRONIC MYELOID LEUKEMIA (CML), INTO CHRONIC DISEASES. DESPITE THE TARGETED APPROACH, VASCULAR TOXICITIES HAVE EMERGED. SPECIFICALLY, THE FIRST-GENERATION CML TKI IMATINIB IS SAFE, YET NEWER GENERATION TKIS FREQUENTLY USED FOR RESISTANT CML (NILOTINIB, DASATINIB, PONATINIB) CONFER A 2-5 FOLD INCREASED RISK OF ARTERIAL THROMBOSIS CAUSING MI, STROKE, OR LIMB ISCHEMIA. WITH NO VALIDATED MODELS TO TEST FOR VASCULAR TOXICITY PRIOR TO DRUG APPROVAL, THIS SIDE EFFECT WAS IDENTIFIED ONLY WHEN ADVERSE EVENTS ACCRUED AND ONCE RECOGNIZED, THERE ARE NO DATA TO GUIDE CLINICIANS AS TO HOW TO PREVENT THIS OR TO TREAT THESE CANCER SURVIVORS. THIS PROPOSAL ADDRESSES THESE GAPS IN KNOWLEDGE BY LEVERAGING THE CML TKIS, A DRUG CLASS WITH BOTH SAFE AND TOXIC MEMBERS. WE AND OTHERS SHOWED THAT TOXIC CML TKIS DAMAGE ECS IN SOME IN VITRO MODELS AND ENHANCE ATHEROSCLEROSIS IN MICE. AS CML PATIENTS WITH UNDERLYING CV RISK FACTORS ARE PREDISPOSED TO TOXICITY, WE HYPOTHESIZE THAT THE TOXIC CML DRUGS IMPAIR SPECIFIC ENDOTHELIAL CELL (EC) FUNCTIONS THAT LEAD TO PLAQUE DEVELOPMENT, INFLAMMATION, RUPTURE, THROMBOSIS AND ISCHEMIA. AS THESE DRUGS ARE KINASE INHIBITORS, WE FURTHER POSIT THAT THE TOXICITY IS CAUSED BY MODULATION OF THE PHOSPHORYLATION STATE OF SIGNALING PROTEINS IN A MANNER THAT IS DELETERIOUS TO EC FUNCTION AND HAVE SHOWN THIS USING PROTEOMIC APPROACHES. THUS, WE NOW PROPOSE TO TEST THE HYPOTHESIS THAT TOXIC CML TKIS ACT ON ECS TO IMPAIR BARRIER INTEGRITY, ENHANCE LEUKOCYTE TRAFFICKING, SLOW WOUND HEALING, AND INCREASE INTERACTION WITH PLATELETS, THEREBY PROMOTING AN ATHEROSCLEROSIS PHENOTYPE PRONE TO RUPTURE AND THROMBOSIS, AND THAT THE DRUG-INDUCED EC PROTEOMIC PROFILE CAN PREDICT VASCULAR TOXICITY AND IDENTIFY MITIGATING TREATMENTS. WE TEST THIS WITH 2 AIMS USING MULTIPLE INNOVATIVE APPROACHES: SA1 INTERROGATES THE IMPACT OF EACH CML TKI USING HUMAN ENGINEERED MICROVESSELS (HEMVS) TO EXAMINE THE IMPACT ON VASCULAR PERMEABILITY AND PLATELET AGGREGATION AND IN MICE USING INTRAVITAL MICROSCOPY TO QUANTIFY LEUKOCYTE-EC INTERACTION, CAROTID WIRE INJURY TO MEASURE VASCULAR RE- ENDOTHELIALIZATION, AND APO-E-KO MICE WITH FACS TO QUANTIFY VASCULAR INFLAMMATION IN ATHEROSCLEROSIS. SA2 USES A TARGETED MASS SPECTROMETRY BASED PHOSPHOPROTEOMIC ASSAY TO PROFILE THE EFFECTS OF EMERGING CML TKIS AND A BROAD RANGE OF DRUGS APPROVED FOR CV DISEASE IN HUMAN ECS TO DETERMINE IF THIS CAN PREDICT TOXICITY OF NEW TKIS AND IDENTIFY MITIGATING THERAPIES. PREDICTED TOXICITIES AND “ANTIDOTES” THAT OPPOSE THE TOXIC PROTEOMIC SIGNATURE WILL BE TESTED USING THE IN VITRO AND IN VIVO MODELS DESCRIBED IN SA1. COMPLETION OF THE AIMS WILL TRANSFORM CARDIOONCOLOGY BY VALIDATING PRECLINICAL MODELS TO PREDICT VASCULAR SAFETY OF CML TKIS AND IDENTIFY POTENTIAL TREATMENTS FOR VASCULAR TOXICITY THAT CAN BE RAPIDLY TRANSLATED TO CARDIOONCOLOGY CARE.

INFECTIOUS DISEASE TRAINING-PATHOGENESIS/HOST RESPONSE

CONSTITUTIONAL AND METABOLIC FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HAND OA

VALUE OF PERSONALIZED RISK INFORMATION

PATHOGENESIS OF CARDIOPULMONARY FIBROSIS ASSOCIATED WITH HEART FAILURE IN THE ELDERLY

MECHANISMS FOR SEX DIFFERENCES IN CVD PATHOLOGY AND DEVELOPMENT OF A TARGETED THERAPEUTIC

THE ROLE OF BONE IN OSTEOARTHRITIS PROGRESSION